Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2018 Filed Dec 4, 2018 21:57 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
GrantDeferred Stock Units · Derivative | 3,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-016173 · doc4.xml · derivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,245 Underlying: Common Stock · 3,245 shares Expires 2023-12-03 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:56 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-016172 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,640 Underlying: Common Stock · 5,000 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:56 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 5,000 | $38.11 | $190,574.00 |
DisclosureSEC source: 0001225208-18-016172 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $38.0943 and $38.1353. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:56 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-18-016172 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:55 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
SaleCommon Stock | 10,000 | $38.00 | $379,994.00 |
DisclosureSEC source: 0001225208-18-016168 · doc4.xml · nonDerivative · entry 3 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,661 F3 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.8201 to $38.20, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:56 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
Exercise / conversionDeferred Stock Units · Derivative | 11,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-016170 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,889 Underlying: Common Stock · 11,472 shares Expires 2022-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:56 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
Tax withholdingCommon Stock | 3,379 | $37.67 | $127,286.93 |
DisclosureSEC source: 0001225208-18-016170 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,679 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:56 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
Exercise / conversionCommon Stock | 11,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-016170 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:56 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionDeferred Stock Units · Derivative | 2,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-016169 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,328 Underlying: Common Stock · 2,327 shares Expires 2019-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:56 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Tax withholdingCommon Stock | 512 | $37.67 | $19,287.04 |
DisclosureSEC source: 0001225208-18-016169 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,698.99 Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:56 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionCommon Stock | 2,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-016169 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,210.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:55 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Exercise / conversionDeferred Stock Units · Derivative | 2,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-016168 · doc4.xml · derivative · entry 4 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,050 Underlying: Common Stock · 2,025 shares Expires 2020-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2016, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2016, the first anniversary of the date of grant. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:55 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Tax withholdingCommon Stock | 912 | $37.67 | $34,355.04 |
DisclosureSEC source: 0001225208-18-016168 · doc4.xml · nonDerivative · entry 2 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,661 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:55 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Exercise / conversionCommon Stock | 2,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-016168 · doc4.xml · nonDerivative · entry 1 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:31 UTC |
FUJIMORI YOSHIAKIDirector
|
SaleCommon Stock | 6,143 | $37.13 | $228,089.59 |
DisclosureSEC source: 0001225208-18-016088 · doc4.xml · nonDerivative · entry 1 FUJIMORI YOSHIAKI · CIK 0001233160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 21:32 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
SaleCommon Stock | 15,298 | $36.74 | $562,019.45 |
DisclosureSEC source: 0001225208-18-016089 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,883.99 F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.73 to $36.78, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 19, 2018 Filed Jan 3, 2019 21:55 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
GiftCommon Stock | 3,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000436 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,052 Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 21:25 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 23,458 | $0.00 Strike: $8.30 | $0.00 |
DisclosureSEC source: 0001225208-18-015657 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,458 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of common stock vesting in four equal annual installments beginning on February 24, 2010, the first anniversary of the date of grant. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 21:25 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
SaleCommon Stock | 23,458 | $37.28 | $874,446.21 |
DisclosureSEC source: 0001225208-18-015657 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,351 F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.27 to $37.30, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 21:25 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 23,458 | $8.30 | $194,701.40 |
DisclosureSEC source: 0001225208-18-015657 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 21:16 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 23,458 | $0.00 Strike: $8.30 | $0.00 |
DisclosureSEC source: 0001225208-18-015461 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,458 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of common stock vesting in four equal annual installments beginning on February 24, 2010, the first anniversary of the date of grant. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 21:16 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
SaleCommon Stock | 23,458 | $37.51 | $879,886.12 |
DisclosureSEC source: 0001225208-18-015461 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,181.99 F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.545, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 21:16 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionCommon Stock | 23,458 | $8.30 | $194,701.40 |
DisclosureSEC source: 0001225208-18-015461 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,639.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 21:10 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
SaleCommon Stock | 4,000 | $38.50 | $154,000.00 |
DisclosureSEC source: 0001225208-18-015458 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,404 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 09, 2018 Filed Jan 3, 2019 21:56 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GiftCommon Stock | 31,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000438 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757,972 Read SEC document |
| November 06, 2018 Filed Jan 3, 2019 21:55 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
GiftCommon Stock | 2,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000433 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,623 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:14 UTC |
Carruthers WendySVP, Human Resources
|
GiftCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015227 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,468 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:14 UTC |
Carruthers WendySVP, Human Resources
|
SaleCommon Stock | 1,500 | $36.64 | $54,964.65 |
DisclosureSEC source: 0001225208-18-015227 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,968 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:13 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-015121 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,640 Underlying: Common Stock · 5,000 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:13 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 5,000 | $36.40 | $181,975.50 |
DisclosureSEC source: 0001225208-18-015121 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $36.3901 and $36.40. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:13 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-18-015121 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:13 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
SaleCommon Stock | 116,666 | $36.35 | $4,240,739.10 |
DisclosureSEC source: 0001225208-18-015120 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,789,772 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.05 to $36.70, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 20:11 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionDeferred Stock Units · Derivative | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-014957 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,697 shares Expires 2018-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 29, 2014, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 29, 2014, the first anniversary of the date of grant. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 20:11 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Tax withholdingCommon Stock | 374 | $35.38 | $13,232.12 |
DisclosureSEC source: 0001225208-18-014957 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,181.99 Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 20:11 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionCommon Stock | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-014957 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,555.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 20:10 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Exercise / conversionDeferred Stock Units · Derivative | 2,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015007 · doc4.xml · derivative · entry 5 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,545 shares Expires 2018-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 29, 2014, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 29, 2014, the first anniversary of the date of grant. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 20:10 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Exercise / conversionCommon Stock | 2,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015007 · doc4.xml · nonDerivative · entry 3 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:24 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-014088 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,640 Underlying: Common Stock · 5,000 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:24 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 5,000 | $38.80 | $194,010.00 |
DisclosureSEC source: 0001225208-18-014088 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $38.7886 and $38.8153. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:24 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-18-014088 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:24 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
SaleCommon Stock | 116,666 | $38.80 | $4,526,465.80 |
DisclosureSEC source: 0001225208-18-014089 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,906,438 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $38.63 to $39.16, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 24, 2018 Filed Sep 25, 2018 20:01 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 37,430 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-18-013738 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,430 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| September 24, 2018 Filed Sep 25, 2018 20:01 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
SaleCommon Stock | 37,430 | $38.00 | $1,422,340.00 |
DisclosureSEC source: 0001225208-18-013738 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,008 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| September 24, 2018 Filed Sep 25, 2018 20:01 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 37,430 | $7.39 | $276,607.70 |
DisclosureSEC source: 0001225208-18-013738 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 20:22 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001225208-18-013324 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 10,000 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 20:22 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
SaleCommon Stock | 10,000 | $35.86 | $358,607.00 |
DisclosureSEC source: 0001225208-18-013324 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,636 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.71 to $36.02, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 20:22 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Exercise / conversionCommon Stock | 10,000 | $13.08 | $130,800.00 |
DisclosureSEC source: 0001225208-18-013324 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 20:29 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
SaleCommon Stock | 10,000 | $35.86 | $358,595.00 |
DisclosureSEC source: 0001225208-18-013326 · doc4.xml · nonDerivative · entry 1 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,162 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.71 to $36.02, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 20:28 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
SaleCommon Stock | 116,666 | $35.88 | $4,186,104.41 |
DisclosureSEC source: 0001225208-18-013325 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,023,104 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.705 to $36.04, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 20:15 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-013152 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,640 Underlying: Common Stock · 5,000 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.